Table 1 Summary of studies monitoring RAS mutations in ctDNA of mCRC patients receiving anti-EGFR therapies
Reference | Methods for ctDNA measurement | Patients (n) | Previous chemotherapy exposure | Anti-EGFR therapy | Rate of detected circulating RAS mutations during treatment (%) | Potential clinical value |
|---|---|---|---|---|---|---|
Diaz LA et al. [13] | BEAMing | 28 | yes | panitumumab | 38 | Circulating KRAS mutations generally occurred 5 to 6 months after anti-EGFR therapy. |
Misale S et al. [14] | Pyrosequencing or BEAMing | 10 | yes | cetuximab or panitumumab | 60 | Circulating KRAS mutations were frequently detected in acquired resistance to anti-EGFR therapies. |
Toledo RA et al. [30] | BEAMing | 23 | no | cetuximab | 13 | Abrupt increase in mutant cfDNA correlated with eminent clinical deterioration. |
Vidal J et al. [31] | BEAMing | 18 | unknown | cetuximab or panitumumab | 39 | Circulating RAS mutations correlated with acquired resistance to anti-EGFR therapies. |